Clinical trial
Study of IV Edotecarin Vs Temozolomide or Carmustine (BCNU) or Lomustine (CCNU)…
NCT00068952 · Pfizer, Industry · Completed
Key facts
| NCT number | NCT00068952 |
|---|---|
| Title | Study of IV Edotecarin Vs Temozolomide or Carmustine (BCNU) or Lomustine (CCNU) in Patients With Glioblastoma Multiforme |
| Official title | A Phase III, Randomized, Open-Label Study Of IV Edotecarin Vs Temozolomide Or Carmustine (BCNU) Or Lomustine (CCNU) In Patients With Glioblastoma Multiforme At First Relapse After Alkylator-Based (NEO) Adjuvant Chemotherapy |
| Lead sponsor | Pfizer, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Glioblastoma |
| Intervention type | Drug |
| Interventions | Edotecarin, Temozolomide, Carmustine (BCNU), Lomustine (CCNU) |
| Enrollment | 118 |
| Start date | Aug 1, 2003 |
| Completion | Mar 1, 2006 |
| First posted | Sep 16, 2003 |
| Last update posted | Apr 1, 2008 |
| Countries | Australia, Austria, Canada, Croatia, Czechia, France, Germany, India, Italy, Russia, South Africa, Spain and 1 more |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: